IDEAYA Biosciences (IDYA) Cash from Financing Activities (2018 - 2026)

IDEAYA Biosciences has reported Cash from Financing Activities for 9 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 95.48% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 98.64% YoY) and the FY2025 annual result came in at $29.8 million, down 95.6% from the prior year.
• Cash from Financing Activities declined to $1.2 million in Q1 2026 per IDYA's latest filing, from $2.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $349.1 million in Q1 2024 and troughed at $301000.0 in Q3 2025.
• A 5-year average of $68.7 million and a median of $2.9 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 43385.8% in 2023, then plunged 99.89% in 2025.
• Over 5 years, Cash from Financing Activities stood at $324000.0 in 2022, then soared by 43385.8% to $140.9 million in 2023, then sank by 98.05% to $2.8 million in 2024, then slipped by 22.63% to $2.1 million in 2025, then plunged by 44.55% to $1.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.2 million, $2.1 million, and $301000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.